Dermatology

>

Latest News

Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years / image credit - Lilly logo: ©Michael Vi/stock.adobe.com
Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years

September 25th 2024

Among adolescents and adults with moderate-to-severe AD, more than 80% achieved sustained disease control, the majority not requiring topical or systemic rescue medication.

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types / Image credit: ©InfiniteStudio/AdobeStock
Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types

September 25th 2024

FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema / image credit atopic dermatitis: ©Ольга Тернавская/stock.adobe.com
FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema

September 24th 2024

FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose

September 24th 2024

Real-World Study Supports Use of DermaSensor in Primary Care to Differentiate Cancerous and Benign Lesions Image credit - DermaSensor logo: ©DermaSensor
Real-World Study Supports Use of DermaSensor in Primary Care to Differentiate Cancerous and Benign Lesions

September 23rd 2024

Latest CME Events & Activities

Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

October 16, 2024

Register Now!

Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)

View More

Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia

View More

Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis

November 21, 2024 - December 5, 2024

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

More News

© 2024 MJH Life Sciences

All rights reserved.